| Synonym |
| Thai / English name |
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 10 mL/kg for turmeric juiceDuration : Single administrationType of interaction : PharmacokineticsInteraction with drug : TacrolimusDose/Conc.(drug) : -Result : PositiveRemark : The AUC values of tacrolimus in the rat pre-treated with grapefruit juice, ginger juice, and turmeric juice were significantly larger than those pre-treated with water. These AUC values were almost equal to the values for those pre-treated with 100% pomelo juice.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : Curcimin (diferuloylmethane)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Bleomycin*/Bleo/BLMDose/Conc.(drug) : -Result : PositiveRemark : The co-incubation of bleomycin with curcumin induced caspase-3, -8 and -9 activities more than their single uses in NT2 cells
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Docetaxel*/TaxotereDose/Conc.(drug) : -Result : PositiveRemark : Type of experiment: Human lung cancer call line A549. Results: Curcumin and docetaxel inhibited cell growth with a dose-dependent manner against A549 cells. The IC50 of curcumin was 10.25+/-1.03 micromolars while the IC50 docetaxel was 4.26+/-0.51 nM against A549 cells and the IC50 of curcumin + docetaxel against A549 cells were 2.81 +/- 0.27 micromolars (curcumin) and 2.81 +/-0.34 nM (docetaxel), respectively. The combination of two drugs generated more cell death than the drugs used singly. The cell inhibition rate of ~ 40% was detected when exposed to the combination of curcumin (2 micromolars) and docetaxel (2 nM) while an inhibition rate of <10% or 20% was observed when cells were treated by the same dose of curcumin or docetaxel,respectively. More obviously, combinational treatment of 0.5 micromolars curcumin and 0.5 nM docetaxel induced a nearly 20% cell death while <5% cell death was observed when curcumin or docetaxel was administered at the same dose singly.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 15 mg/kgDuration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Docetaxel*/TaxotereDose/Conc.(drug) : Docetaxel administered at dose of 10 mg/kg.Result : PositiveRemark : Results: The combination of curcumin and docetaxel inhibited the growth of tumor more effciently than single delivery of curcumin of curcumin (P = 0.01 vs. Doc). At the end of treatment, the relative tumor volume and tumor inhibition rate was 4.19+/-1.39 and 28.3%, which was the lowest among all the groups indicating the strongest tumor inhibition. Additionally, simultaneous administration of curcumin and docetaxel showed little toxicity to normal tissue including bone marrow and liver at the therapeutic doses.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 31 mg/kgDuration : -Type of interaction : PharmacokineticsInteraction with drug : DiclofenacDose/Conc.(drug) : -Result : PositiveRemark : The interaction between diclofenac (10 mg/kg) and curcumin (31 mg/kg) that mediates the antinociceptive effect was synergistic.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : Curcumin-475 mg capsuleType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 8N(Treatment) : 8Sex : -Age : 32 - 38 yrs.Route : Oral administrationDose/Conc.(herb) : curcumin-475mg capsules/dayDuration : Following the administration of Daonil-5 mg, blood samples (1 mL) were collected from the patients at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24h. Patients were treated with curcumin-475mg capsules for the next 10 consecutive days, one capsule per day. During treatment period, patients received both curcumin and Daonil. On the 11th day of the study following the administration of curcumin along with Daonil 5 mg, blood samples (1 mL) were collected once again at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h.Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : Daonil*/Glyburide/Glibenclamide/Diadeta/Glybenclamide/GlybenzcyclamideDose/Conc.(drug) : -Result : PositiveRemark : Result: Glyburide concentrations changed at the second hour, Cmax was unchanged, the glucose levels were decreased, Area Under first Movement Curre (AUMC) was increased significantly, and no patient has experienced the hypoglycaemia. The co-administration of curcumin capsules with glyburide may be beneficial to the patients in better glycaemic control.Note : Subject total: Subjects were type-2 diabetic patients.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : non specifiedType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : None known. Curcumin inhibits P-gp, but has very poor oral bioavailability. Caution in patients taking high doses with anticoagulants or antiplatelet drugs.Note : Data from review, data incomplete.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : -Result : PositiveRemark : Curcumin inhibited P-gp-mediated efflux of rhodamine 123 and enhanced cytotoxicity of vinblastine at short time exposure (1-2 h).Note : Data from review
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminnoids (curcumin I, II, III)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : -Result : PositiveRemark : Type of experiment: Human cervical arcinoma cell line (KB-V1). Results: Treating the cells with non-toxic dose of curcuminnoids increased their sensitivity to vinblastine only in the P-gp expressing drug resistant cell line KB-V1; and curcumin I retained the drug in KB-V1 cells more effectively than curcumin II and III, repectively.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : capsaicin, curcumin, [6]-gingerol, and resveratrol, have inhibitory effects on P-glycoprotein and potencies to cause drug-food interactionsNote : Data incomplete
